Todos Medical Announces Insolvency Proceedings in Israel
#Investment #Management Changes #Customers
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
undefined
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
#Investment
Todos Medical's Letter of Intent with Provista Diagnostics set to license sepsis diagnostic testing
#Partners
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
undefined
Todos Medical Begins Trading on the OTC Pink Marketplace
undefined
Todos Medical Supports Long COVID Awareness Day
#Customers, Expand
Todos Medical Supports Long COVID Awareness Day
undefined
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
#Investment #Partners
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
undefined
Todos Medical releases corporate update around validation plan for PCR-based Avian Influenza testing
#Investment
Todos Medical Provides Corporate Update
undefined
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics
undefined
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
undefined
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022
#Customers, Expand
Todos Medical to Attend World Antiviral Congress
undefined
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
undefined
Todos Medical Announces Third Quarter 2022 Financial Results
undefined
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
undefined
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A.
undefined
Todos Medical Announces BioFuture™ NYC 2022 Presentation
undefined
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA
undefined
Presenting on the Emerging Growth Conference on October 12 Register Now
undefined
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics
undefined
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
undefined
Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test
#Partners #Customers
Todos Medical Announces Strategic Investment by Yozma Group Korea
#Investment
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky
#Customers #Partners
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020
#Customers #Investment
https://www.jpost.com/israel-news/israeli-diagnostic-company-partners-with-aid-genomics-on-covid-19-testing-643701
#Partners
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma
undefined
Nationwide On-Site Coronavirus Testing Program
#Partners #Customers
Todos Medical Enters Into Distribution Partnership With Meridian Health Services Network for COVID-19 Testing Solutions
undefined
Todos Medical Enters Into Exclusive Distribution Agreement With NLC Pharma for Saliva-based Onsite COVID-19 Diagnostic Test
#Partners #Investment
Todos Medical Expands on Coronavirus (COVID-19) Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar
#Customers #Partners
https://www.jpost.com/jpost-tech/hillels-tech-corner-todos-medical-revisited-amid-the-corona-pandemic-622591
#Customers #Partners
Todos Medical Signs Novel Coronavirus (COVID-19) Point-of-Care Rapid Antibody Testing Kit Exclusive Distribution Agreement for the United States and Israel with Shanghai Liangrun Subsidiary Gibraltar
undefined
Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
#Partners
Todos Medical Receives Notice of Allowance from European Patent Office Covering Diagnosis of Solid Tumors Using AI to Analyze Blood
#Partners
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes
#Acquisition #Management Changes
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries
#Partners
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer's Blood Diagnostic LymPro Test 2.0
#Partners #Investment
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors
#Management Changes
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
#Investment #Acquisition
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)
#Customers
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer
#Customers
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria
#Partners
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer
#Management Changes
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel
#Customers
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening
#Customers
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents
#Customers
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer
#Management Changes
Todos Medical files for Wall St IPO
#Investment